Blain M Mamiya

US Patent:

6593306, Jul 15, 2003

Filed:

Dec 21, 1999

Appl. No.:

09/467932

Inventors:

Shih-Fong Chen - San Antonio TX
Ira Maine - San Antonio TX
Sean M. Kerwin - Round Rock TX
Terace M. Fletcher - San Antonio TX
Miquel Salazar - Austin TX
Blain Mamiya - Austin TX
Makoto Wajima - San Antonio TX
Bradford E. Windle - San Antonio TX

Assignee:

Board of Regents, The University of Texas Systems - Austin TX
CTRC Research Foundation - San Antonio TX

International Classification:

A61K 3170

US Classification:

514 45, 514 43, 514 48

Abstract:

It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2â-deoxyquanosine-5â-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA. The nucleoside analogs were found to be capable of a variety of activities including mediating allosteric-like inhibition of telomerase, premature termination and shortening of telomeric DNA, destabilization of telomeric structure and function and eventually cell death. Understanding the mechanisms of telomerase modulation by the 7-deaza-nucleotides has allowed the design of new telomerase inhibitors, modulators and agents for affecting telomere structure and function.

US Patent:

57564795, May 26, 1998

Filed:

May 24, 1995

Appl. No.:

8/449311

Inventors:

Creed W. Abell - Austin TX
Sau-Wah Kwan - Austin TX
Binhua Zhou - Austin TX
Blain M. Mamiya - Austin TX
Duane A. Lewis - Austin TX

Assignee:

Research Development Foundation - Carson City NV

International Classification:

A61K 3170
C07H 19207

US Classification:

514 47

Abstract:

The present invention provides an inhibitor of monoamine oxidase comprising a modified synthetic flavin adenine dinucleotide compound. Also provided is a method of inhibiting monoamine oxidase enzymatic activity in a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a modified synthetic flavin adenine dinucleotide compound. Further provided is a method of treating a brain pathophysiological state in an individual, comprising administering a therapeutically effective dose of a modified synthetic flavin adenine dinucleotide compound to said individual.

US Patent:

60544422, Apr 25, 2000

Filed:

Jul 3, 1996

Appl. No.:

8/675119

Inventors:

Shih-Fong Chen - San Antonio TX
Ira Maine - San Antonio TX
Sean M. Kerwin - Round Rock TX
Terace M. Fletcher - San Antonio TX
Miguel Salazar - Austin TX
Blain Mamiya - Austin TX
Bradford E. Windle - San Antonio TX
Makoto Wajima - San Antonio TX

Assignee:

Board of Regents, University of Texas System - Austin
CTRC Research Foundation - San Antonio TX

International Classification:

A61K 3170
C07H 1914

US Classification:

514 45

Abstract:

It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA. The nucleoside analogs were found to be capable of a variety of activities including mediating allosteric-like inhibition of telomerase, premature termination and shortening of telomeric DNA, destabilization of telomeric structure and function and eventually cell death. Understanding the mechanisms of telomerase modulation by the 7-deaza-nucleotides has allowed the design of new telomerase inhibitors, modulators and agents for affecting telomere structure and function.

US Patent:

60049391, Dec 21, 1999

Filed:

Jun 20, 1997

Appl. No.:

8/879457

Inventors:

Shih-Fong Chen - San Antonio TX
Ira Maine - San Antonio TX
Sean M. Kerwin - Round Rock TX
Terace M. Fletcher - San Antonio TX
Miquel Salazar - Austin TX
Blain Mamiya - Austin TX
Makoto Wajima - San Antonio TX
Bradford E. Windle - San Antonio TX

Assignee:

CTRC Research Foundation Board of Regents - San Antonio TX
The University of Texas System - Austin TX

International Classification:

A61K 3170

US Classification:

514 43

Abstract:

It was found that normal human stem cells produce a regulated non-processive telomerase activity, while cancer cells produce a processive telomerase activity. Nucleotide analogs, such as 7-deaza-2'-deoxyquanosine-5'-triphosphate (7-deaza-dGTP) were found to be substrates for processive telomerase and incorporated into telomeric sequence. The incorporation of this nucleotide subsequently affected the processivity of telomerase, converting processive telomerase to non-processive telomerase. The incorporation of this nucleotide analogs was also found to inhibit formation of G-quartets by telomeric sequence. Other methods for converting cancer processive telomerase to the more benign non-processive telomerase include partially cleaving the telomerase RNA. The nucleoside analogs were found to be capable of a variety of activities including mediating allosteric-like inhibition of telomerase, premature termination and shortening of telomeric DNA, destabilization of telomeric structure and function and eventually cell death. Understanding the mechanisms of telomerase modulation by the 7-deazanucleotides has allowed the design of new telomerase inhibitors, modulators and agents for affecting telomere structure and function.